Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (2010) 1.77

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother (2007) 1.38

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol (2004) 1.12

Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther (2009) 1.04

Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. PLoS One (2009) 1.01

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother (2011) 0.95

In vivo Treg suppression assays. Methods Mol Biol (2011) 0.95

Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes. Int J Immunopathol Pharmacol (2006) 0.93

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood (2007) 0.89

β-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the growth of implanted murine melanoma in vivo. PLoS One (2012) 0.87

Using the TAP component of the antigen-processing machinery as a molecular adjuvant. PLoS Pathog (2005) 0.84

Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides. Clin Immunol (2007) 0.83

Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells. PLoS One (2010) 0.82

Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol (2012) 0.80

In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun (2009) 0.80

DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol (2010) 0.80

The aged nonhematopoietic environment impairs natural killer cell maturation and function. Aging Cell (2015) 0.79

The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS One (2013) 0.79

Expression of major histocompatibility complex class I proteins and their antigen processing chaperones in mouse embryonic stem cells from fertilized and parthenogenetic embryos. Tissue Antigens (2008) 0.79

Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. Cancer Immunol Immunother (2011) 0.78

The role of tapasin in MHC class I protein trafficking in embryos and T cells. J Reprod Immunol (2007) 0.78

Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther (2012) 0.77

The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells. Cancer Immun (2008) 0.77

An ENU mutagenesis approach to dissect "self"-induced immune responses: Unraveling the genetic footprint of immunosurveillance. Oncoimmunology (2012) 0.77

NLRC5, a promising new entry in tumor immunology. J Immunother Cancer (2016) 0.77

Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Ther (2015) 0.76

NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes. Oncoimmunology (2016) 0.76

Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clin Cancer Res (2015) 0.75

Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS). Sci Rep (2016) 0.75

Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid. Oncoimmunology (2016) 0.75

High-resolution record of Northern Hemisphere climate extending into the last interglacial period. Nature (2004) 6.44

Serum levels of cytokines in chronic liver diseases. Gastroenterology (1992) 3.47

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31

Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med (2000) 3.26

A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15

CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity (2000) 3.07

Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science (1993) 3.06

Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell (1991) 2.83

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79

B cells inhibit induction of T cell-dependent tumor immunity. Nat Med (1998) 2.50

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49

A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity (1997) 2.45

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature (1996) 2.30

Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res (1987) 2.22

Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99

Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. J Immunol (1986) 1.82

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79

T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74

Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. Eur J Immunol (1992) 1.67

Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med (1991) 1.64

Kinetic analysis of cytokine gene expression in the livers of naive and immune mice infected with Listeria monocytogenes. The immediate early phase in innate resistance and acquired immunity. J Immunol (1992) 1.63

The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol (1981) 1.53

Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer (1986) 1.48

Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation (1983) 1.47

Sulphate transporter gene mutations in apparently isolated club foot. J Med Genet (2001) 1.47

Aniline blue staining as a marker of sperm chromatin defects associated with different semen characteristics discriminates between proven fertile and suspected infertile men. Int J Androl (1990) 1.46

Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol (2000) 1.44

Non-deletional mechanisms of peripheral and central tolerance: studies with transgenic mice with tissue-specific expression of a foreign MHC class I antigen. Immunol Rev (1991) 1.43

Further evidence for lymphokine overproduction in severe aplastic anemia. Blood (1988) 1.43

Effectiveness of intraocular lens calculation in high ametropia. J Cataract Refract Surg (1989) 1.42

Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity (2000) 1.41

Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood (1996) 1.41

Cell biology of antigen presentation. Curr Opin Immunol (1993) 1.39

Epidural butorphanol does not reduce side effects from epidural morphine after cesarean birth. Anesth Analg (1994) 1.39

Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol (1992) 1.37

Human autologous mixed lymphocyte reactivity is primarily specific for xenoprotein determinants adsorbed to antigen-presenting cells during rosette formation with sheep erythrocytes. J Exp Med (1982) 1.37

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36

Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med (1994) 1.36

Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol (1983) 1.34

Distinct mechanisms of extrathymic T cell tolerance due to differential expression of self antigen. Int Immunol (1992) 1.32

A polymorphic microsatellite in the tumor necrosis factor alpha promoter identifies an allele unique to the NZW mouse strain. J Exp Med (1990) 1.31

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med (2001) 1.30

Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer (1987) 1.30

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci U S A (1993) 1.27

Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol (1997) 1.27

State dependent dissociation of HERG channel inhibitors. Br J Pharmacol (2007) 1.27

Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 1.25

Translocation of long peptides by transporters associated with antigen processing (TAP). Eur J Immunol (1996) 1.22

Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med (2001) 1.22

The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22

Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos (1998) 1.20

Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol Immunol (1990) 1.19

Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res (1993) 1.19

Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation (1990) 1.18

T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med (1999) 1.18

The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta (1987) 1.17

Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res (1998) 1.17

Liver transplantation followed by high-dose cyclophosphamide, total-body irradiation, and autologous bone marrow transplantation for treatment of metastatic breast cancer. A case report. Transplantation (1984) 1.16

In vivo induction of H-2K/D antigens by recombinant interferon-gamma. Eur J Immunol (1986) 1.15

Expression of interleukin 10 in human melanoma. Br J Cancer (1994) 1.15

Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol (1996) 1.15

Biosynthesis and metabolism of pterins in peripheral blood mononuclear cells and leukemia lines of man and mouse. Eur J Biochem (1987) 1.15

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol (1995) 1.14

Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med (1990) 1.14

Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome (AIDS). A preliminary report. Hoppe Seylers Z Physiol Chem (1983) 1.14

Analysis of the structure-function relationship of the S-layer protein SbsC of Bacillus stearothermophilus ATCC 12980 by producing truncated forms. Microbiology (2001) 1.14

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther (2010) 1.14

Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol (1993) 1.13

Analysis of the fine specificity of rat, mouse and human TAP peptide transporters. Eur J Immunol (1995) 1.13

Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer (1987) 1.13

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant (2005) 1.13

Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood (1987) 1.12

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer (2003) 1.12

Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J Gen Virol (1996) 1.12

The chronology of third molar mineralization in the Austrian population--a contribution to forensic age estimation. Forensic Sci Int (2006) 1.11

Interferon-gamma enhances biosynthesis of pterins in peripheral blood mononuclear cells by induction of GTP-cyclohydrolase I activity. J Interferon Res (1986) 1.11

Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res (1999) 1.10

Zinc deficiency and zinc repletion: effect on the response of rats to infection with Trichinella spiralis. Am J Clin Nutr (1990) 1.09

Folding and assembly of major histocompatibility complex class I heterodimers in the endoplasmic reticulum of intact cells precedes the binding of peptide. J Exp Med (1993) 1.08

Planned myopic astigmatism as a substitute for accommodation in pseudophakia. J Am Intraocul Implant Soc (1981) 1.08

Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol (1998) 1.07

Cyclosporin blood levels do correlate with clinical complications. Lancet (1984) 1.07

Combined liver and kidney transplantation. Lancet (1984) 1.07

Generation of competitor DNA fragments for quantitative PCR. PCR Methods Appl (1991) 1.07

IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol (1988) 1.06

The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol (1997) 1.05

RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. Hum Gene Ther (1998) 1.04

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol (2001) 1.04

Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res (1991) 1.03

Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol (1994) 1.03

Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant (2006) 1.03

Isoalloxazine derivatives promote photocleavage of natural RNAs at G.U base pairs embedded within helices. Nucleic Acids Res (1997) 1.03

TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T lymphocytes. Eur J Immunol (1993) 1.03

Antigen presentation of hen egg-white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II-associated invariant chain. Eur J Immunol (1991) 1.02

Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol (2001) 1.01

The human immunoglobulin kappa locus. Characterization of the duplicated A regions. Eur J Immunol (1992) 1.01

Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation (1984) 1.01

Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol (1997) 1.01